This study explores the role of microRNAs (miRNAs) in patients with COVID-19 in Babylon Province, focusing on their potential as biomarkers for disease progression and clinical outcomes. miRNAs are small non-coding RNAs that regulate gene expression and have been implicated in various biological processes, including immune response and inflammation. We conducted a cross-sectional analysis of COVID-19 patients to assess the expression levels of specific miRNAs and their association with disease severity, inflammation markers, and patient demographics. Our findings reveal distinct miRNA profiles that correlate with adverse outcomes in COVID-19, suggesting their potential utility in predicting disease severity and guiding therapeutic strategies. This work highlights the need for further investigation into the functional roles of miRNAs in COVID-19 pathophysiology and their possible application as biomarkers for monitoring disease progression and treatment response.

The study found a significant increase in miR-423 and miR-195 levels in COVID-19 patients compared to the control group. The miR-23a level was notably reduced in COVID-19 patients compared to the control group.

Keywords: miRNAs, COVID-19, biomarkers, Babylon Province, disease progression, inflammation, gene expression,